Expect to See Adakveo or Oxbryta for Some Sickle Cell Patients

March 2020

Adakveo (ah-DAK-vee-oh, crizanlizumab) and Oxbryta (oks-BRYE-tuh, voxelotor) will be new meds for sickle cell disease.

They may be added to hydroxyurea...the first-line option to reduce pain crises, hospitalizations, and possibly improve survival.

And they’ll compete with oral Endari (L-glutamine)...which seems to reduce pain crises and possibly hospitalizations.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Migraine Don’t Jump to Ubrelvy or Reyvow for Acute Migraine Treatment
Infection Control Reinforce Infection Control In Light of Coronavirus
Women's Health Stick With Tried and True Treatments for Menstrual Symptoms
Vitamins & Minerals Share the Latest Answers About Vitamin D
Vaccines Feel Comfortable Using Tdap for Routine Tetanus Vaccinations
Osteoarthritis Help Patients Navigate Osteoarthritis Treatments
Testosterone Weigh Risks and Benefits of Testosterone for “Low T”
Hypertension Guide Staff in Triaging Calls About Severely Elevated BP
Sickle Cell Disease Expect to See Adakveo or Oxbryta for Some Sickle Cell Patients
Transitions of Care Reduce Errors During Transitions to Outside Facilities